Other languages Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Real-time Estimate Cboe BZX Other stock markets 07:04:53 01/05/2024 pm IST			5-day change	1st Jan Change
10.04 ^USD	+0.55%		-6.72%	-29.60%

18/03	JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	MT
05/03	Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	06/03
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises	28/02
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	28/02
Amicus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Amicus Therapeutics Insider Sold Shares Worth $390,018, According to a Recent SEC Filing	09/02
Amicus Therapeutics Insider Sold Shares Worth $683,958, According to a Recent SEC Filing	25/01
Amicus Therapeutics Insider Sold Shares Worth $404,106, According to a Recent SEC Filing	19/01
Amicus Therapeutics Insider Sold Shares Worth $934,659, According to a Recent SEC Filing	12/01
Amicus Therapeutics Insider Sold Shares Worth $449,545, According to a Recent SEC Filing	10/01
Amicus Therapeutics Sees Revenue Growth of 21% in 2023	08/01
Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024	08/01
Amicus Therapeutics Insider Sold Shares Worth $734,007, According to a Recent SEC Filing	05/01
Amicus Therapeutics Insider Sold Shares Worth $490,411, According to a Recent SEC Filing	29/12
Amicus Therapeutics Insider Sold Shares Worth $253,542, According to a Recent SEC Filing	21/12
Amicus Therapeutics Shares Climb After Morgan Stanley Upgrade	20/12
Amicus Therapeutics Insider Sold Shares Worth $129,693, According to a Recent SEC Filing	06/12
Amicus Therapeutics Announces Executive Changes	05/12
Amicus Therapeutics' Q3 Net Loss Narrows, Revenue Rises	08/11
Amicus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Amicus Therapeutics Insider Sold Shares Worth $131,489, According to a Recent SEC Filing	05/23/05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Other languages

Filters